Lilly's oral GLP‑1 approved

Eli Lilly now has a Food and Drug Administration-approved daily obesity pill in the United States: Foundayo, the brand name for orforglipron. (fda.gov) The Food and Drug Administration said on April 1 that it approved Foundayo for adults with obesity, or adults who are overweight and have weight-related medical problems. The agency said the decision came 50 days after filing and 294 days before the application’s January 20, 2027 user-fee deadline. (fda.gov) Orforglipron works by activating the glucagon-like peptide-1 receptor, the same appetite-and-blood-sugar pathway targeted by injectable drugs such as Wegovy and Zepbound. Lilly said Foundayo is the only glucagon-like peptide-1 pill for weight loss that can be taken any time of day without food or water restrictions. (accessdata.fda.gov, finance.yahoo.com) The label calls for a step-up dosing schedule that starts at 0.8 milligrams once daily, rises to 2.5 milligrams after at least 30 days, then to 5.5 milligrams after another 30 days, with optional increases up to 17.2 milligrams. The same label carries the boxed thyroid tumor warning used on other drugs in this class and lists nausea, diarrhea, vomiting, constipation, stomach pain, headache and indigestion among common side effects. (accessdata.fda.gov) Lilly’s late-stage obesity program put a number on what the pill can do. In the 72-week ATTAIN-1 trial, Lilly said patients on the highest dose lost an average of 27.3 pounds, or 12.4% of body weight, versus 2.2 pounds on placebo. (prnewswire.com) The pill arrives as Lilly is also changing how patients get its injectable obesity drug. On February 23, Lilly said Zepbound would be sold in a multi-dose KwikPen that delivers four weekly doses from one device, with self-pay prices starting at $299 a month for 2.5 milligrams and $399 for 5 milligrams through LillyDirect. (prnewswire.com) That gives Lilly a broader obesity lineup: a daily pill, a once-weekly injectable, and newer compounds still in testing. In December 2025, Lilly said its experimental weekly drug retatrutide cut body weight by 28.7% at 68 weeks in a Phase 3 trial in people with obesity and knee osteoarthritis. (prnewswire.com) The competitive backdrop has changed quickly over the past year. Managed Healthcare Executive reported that Novo Nordisk’s oral Wegovy won United States approval in December 2025, setting up a head-to-head market between Lilly’s new pill and Novo’s tablet entry. (managedhealthcareexecutive.com) Foundayo is already moving into commercial channels days after approval. LifeMD said on April 10 that it had begun offering the drug, a sign that Lilly’s obesity business is now selling pills and pens at the same time while larger outcome and Phase 3 data continue to build around the next wave of products. (markets.businessinsider.com, lilly.mediaroom.com)